Cinpanemab fails to slow disease progression in patients with early Parkinson’s disease: NEJM

Cinpanemab fails to slow disease progression in patients with early Parkinson’s disease: NEJM
Globally, Parkinson's disease is the numerically fastest growing and the second most common neurodegenerative disorder. In Parkinson's disease, dopamine replacement has a substantial benefit ... read more
Source: Bing NewsPublished on 2022-08-04